joae tirzepatide glp-1 Stopping Receptor Agonists… Why and How to Plan an “Exit Strategy” for Your Patients Tirzepatide is a New Medication

Gennigens C, Menetrier-Caux C, Droz JP

Furthermore, in January 2025, the FDA approved semaglutide (Ozempic ) for reducing the risk of kidney failure and disease progression in patients with diabetes and chronic kidney disease (CKD), making it the first GLP-1 agent indicated for the treatment of CKD (Perkovic et al., 2024)

Clinical Evidence on Combining GLP-1 Agonists With Growth Hormone Peptides Published clinical trials on sermorelin plus GLP-1 receptor agonists are limited, but emerging real-world evidence suggests combination therapy can be tolerated in carefully selected patients

If you're a commercial driver and you're worried about your weight, let this be your sign to do something about it

Remember that GLP-1 medicine is just one tool

monash.edu/medicine/mchri/pcos Gougeon A